Suggested remit: To appraise the clinical and cost effectiveness of belantamab mafodotin within its marketing authorisation for treating relapsed or refractory multiple myeloma after 4 or more therapies.
Please note that following on from information provided to NICE by the company in November 2024, the appraisal was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued
- Status:
- Discontinued
- Technology type:
- Medicine
- Decision:
- Prioritised
- Process:
- STA Standard
- ID number:
- 2701
Email enquiries
If you have any queries please email nice@nice.org.uk
- External Assessment Group:
- Peninsula Technology Assessment Group (PenTAG), University of Exeter
Stakeholders
- Companies sponsors
- GlaxoSmithKline (belantamab mafodotin)
- Others
- Department of Health and Social Care
- NHS England
- Welsh Government
- Patient carer groups
- Blood Cancer UK
- Myeloma UK
- Professional groups
- Association of Cancer Physicians
- Cancer Research UK
- Royal College of Physicians
- Royal College of Radiologists
- Comparator companies
- Bristol Myers Squibb (pomalidomide and thalidomide)
- Janssen-Cilag (bortezomib)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- Scottish Medicines Consortium
- Welsh Health Specialised Services Committee
- Relevant research groups
- Institute of Cancer Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 10 February 2026 | Discontinued. Please note that following on from information provided to NICE by the company in November 2024, the appraisal was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued |
| 16 October 2024 | Suspended. Suspended |
| 16 October 2024 | Note - Note added to the project documents |
| 19 October 2023 | Note added to the project documents |
| 07 September 2023 | Appeal |
| 14 June 2023 | Committee meeting: 2 |
| 09 May 2023 - 31 May 2023 | Draft guidance |
| 13 April 2023 | Committee meeting |
| 02 August 2022 | Invitation to participate |
| 01 June 2022 - 01 July 2022 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 01 June 2022 | Note added to the project documents |
| 24 January 2020 | In progress. Topic is in progress |
For further information on our processes and methods, please see our CHTE processes and methods manual